|
1
|
Sitarz R, Skierucha M, Mielko J, Offerhaus
GJA, Maciejewski R and Polkowski WP: Gastric cancer: Epidemiology,
prevention, classification, and treatment. Cancer Manag Res.
10:239–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fock KM: Review article: The epidemiology
and prevention of gastric cancer. Aliment Pharmacol Ther.
40:250–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ang TL and Fock KM: Clinical epidemiology
of gastric cancer. Singapore Med J. 55:621–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jang JY and Chun HJ: Efficacy of
Helicobacter pylori eradication for the prevention of metachronous
gastric cancer after endoscopic resection for early gastric cancer.
World J Gastroenterol. 20:2760–2764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meyer HJ and Wilke H: Treatment strategies
in gastric cancer. Dtsch Arztebl Int. 108:698–705. 2011.PubMed/NCBI
|
|
6
|
Peters MD: Postsurgical chemotherapy vs.
surgery alone for resectable gastric cancer. Am J Nurs. 114:242014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J
and Sung JJ: MicroRNA dysregulation in gastric cancer: A new player
enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y, Fang Y, Liu Y and Yang X: MicroRNAs
in ovarian function and disorders. J Ovarian Res. 8:512015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu D, Chen H, Yang X, Chen W, Wang L, Xu
J and Yu L: miR-32 functions as a tumor suppressor and directly
targets SOX9 in human non-small cell lung cancer. Onco Targets
Ther. 8:1773–1783. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen
TD: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murakami Y, Yasuda T, Saigo K, Urashima T,
Toyoda H, Okanoue T and Shimotohno K: Comprehensive analysis of
microRNA expression patterns in hepatocellular carcinoma and
non-tumorous tissues. Oncogene. 25:2537–2545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W,
Liu J, Yu J and Chen J: miRNA-96 suppresses KRAS and functions as a
tumor suppressor gene in pancreatic cancer. Cancer Res.
70:6015–6025. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu
W, Yang K, He X and Chen S: MicroRNA-21 acts as an oncomir through
multiple targets in human hepatocellular carcinoma. J Hepatol.
53:98–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hui A, How C, Ito E and Liu FF: Micro-RNAs
as diagnostic or prognostic markers in human epithelial
malignancies. BMC Cancer. 11:5002011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Colamaio M, Puca F, Ragozzino E, Gemei M,
Decaussin-Petrucci M, Aiello C, Bastos AU, Federico A, Chiappetta
G, Del Vecchio L, et al: miR-142-3p downregulation contributes to
thyroid follicular tumorigenesis by targeting ASH1L and MLL1. J
Clin Endocrinol Metab. 100:E59–E69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chai S, Tong M, Ng KY, Kwan PS, Chan YP,
Fung TM, Wong N, Xie D, Yuan YF, Guan XY and Ma S: Regulatory role
of miR-142-3p on the functional hepatic cancer stem cell marker
CD133. Oncotarget. 5:5725–5735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu S, Wei J, Wang F, Kong LY, Ling XY,
Nduom E, Gabrusiewicz K, Doucette T, Yang Y, Yaghi NK, et al:
Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy
against murine glioblastoma. J Natl Cancer Inst.
106:pii:dju1622014. View Article : Google Scholar
|
|
19
|
Xu G, Wang J, Jia Y, Shen F, Han W and
Kang Y: MiR-142-3p functions as a potential tumor suppressor in
human osteosarcoma by targeting HMGA1. Cell Physiol Biochem.
33:1329–1339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lei Z, Xu G, Wang L, Yang H, Liu X, Zhao J
and Zhang HT: MiR-142-3p represses TGF-β-induced growth inhibition
through repression of TGFβR1 in non-small cell lung cancer. FASEB
J. 28:2696–2704. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dou L, Li J, Zheng D, Li Y, Gao X, Xu C,
Gao L, Wang L and Yu L: MicroRNA-142-3p inhibits cell proliferation
in human acute lymphoblastic leukemia by targeting the MLL-AF4
oncogene. Mol Biol Rep. 40:6811–6819. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang XS, Gong JN, Yu J, Wang F, Zhang XH,
Yin XL, Tan ZQ, Luo ZM, Yang GH, Shen C and Zhang JW: MicroRNA-29a
and microRNA-142-3p are regulators of myeloid differentiation and
acute myeloid leukemia. Blood. 119:4992–5004. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen WW, Zeng Z, Zhu WX and Fu GH:
MiR-142-3p functions as a tumor suppressor by targeting CD133,
ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl).
91:989–1000. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Carlson RW, Allred DC, Anderson BO,
Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ,
Gradishar WJ, et al: Breast cancer. Clinical practice guidelines in
oncology. J Natl Compr Canc Netw. 7:122–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
de Falco G and Giordano A: CDK9 (PITALRE):
A multifunctional multifunctional cdc2-related kinase. J Cell
Physiol. 177:501–506. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
De Luca A, Esposito V, Baldi A, Claudio
PP, Fu Y, Caputi M, Pisano MM, Baldi F and Giordano A: CDC2-related
kinase PITALRE phosphorylates pRb exclusively on serine and is
widely expressed in human tissues. J Cell Physiol. 172:265–273.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Simone C, Bagella L, Bellan C and Giordano
A: Physical interaction between pRb and cdk9/cyclinT2 complex.
Oncogene. 21:4158–4165. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Napolitano G, Licciardo P, Gallo P,
Majello B, Giordano A and Lania L: The CDK9-associated cyclins T1
and T2 exert opposite effects on HIV-1 Tat activity. AIDS.
13:1453–1459. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deng B, Zhang Y, Zhang S, Wen F, Miao Y
and Guo K: MicroRNA-142-3p inhibits cell proliferation and invasion
of cervical cancer cells by targeting FZD7. Tumour Biol.
36:8065–8073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu L, Cai C, Wang X, Liu M, Li X and Tang
H: MicroRNA-142-3p, a new regulator of RAC1, suppresses the
migration and invasion of hepatocellular carcinoma cells. FEBS
Lett. 585:1322–1330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Inoue T, Iinuma H, Ogawa E, Inaba T and
Fukushima R: Clinicopathological and prognostic significance of
microRNA-107 and its relationship to DICER1 mRNA expression in
gastric cancer. Oncol Rep. 27:1759–1764. 2012.PubMed/NCBI
|
|
33
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Krützfeldt J: Strategies to use microRNAs
as therapeutic targets. Best Pract Res Clin Endocrinol Metab.
30:551–561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wei P, Gender ME, Fang SM, Fisher WH and
Jones KA: A novel CDK9-associated C-type cyclin interacts directly
with HIV-1 Tat and mediates its high-affinity, loop-specific
binding to TAR RNA. Cell. 92:451–462. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kohoutek J, Li Q, Blazek D, Luo Z, Jiang H
and Peterlin BM: Cyclin T2 is essential for mouse embryogenesis.
Mol Cell Biol. 29:3280–3285. 2009. View Article : Google Scholar : PubMed/NCBI
|
